Cargando…

Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors

Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yilin, Yan, Yong, Liang, Lufan, Feng, Jie, Wang, Xuejun, Li, Li, Yang, Kewu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471427/
https://www.ncbi.nlm.nih.gov/pubmed/30934584
http://dx.doi.org/10.3390/molecules24061174
_version_ 1783412026677133312
author Zhang, Yilin
Yan, Yong
Liang, Lufan
Feng, Jie
Wang, Xuejun
Li, Li
Yang, Kewu
author_facet Zhang, Yilin
Yan, Yong
Liang, Lufan
Feng, Jie
Wang, Xuejun
Li, Li
Yang, Kewu
author_sort Zhang, Yilin
collection PubMed
description Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibitors. All the compounds displayed inhibitory activity against ImiS with an IC(50) value range of 0.032–15.64 μM except 7. The chlorine substituted compounds (1, 2 and 3) inhibited NDM-1 with an IC(50) value of less than 0.96 μM, and the fluorine substituted 12 and 13 inhibited VIM-2 with IC(50) values of 38.9 and 2.8 μM, respectively. However, none of the triazolethioacetamides exhibited activity against L1 at inhibitor concentrations of up to 1 mM. Enzyme inhibition kinetics revealed that 9 and 13 are mixed inhibitors for ImiS with K(i) values of 0.074 and 0.27μM using imipenem as the substrate. Docking studies showed that 1 and 9, which have the highest inhibitory activity against ImiS, fit the binding site of CphA as a replacement of ImiS via stable interactions between the triazole group bridging ASP120 and hydroxyl group bridging ASN233.
format Online
Article
Text
id pubmed-6471427
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64714272019-04-26 Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors Zhang, Yilin Yan, Yong Liang, Lufan Feng, Jie Wang, Xuejun Li, Li Yang, Kewu Molecules Communication Metallo-β-lactamases (MβLs) are the target enzymes of β-lactam antibiotic resistance, and there are no effective inhibitors against MβLs available for clinic so far. In this study, thirteen halogen-substituted triazolethioacetamides were designed and synthesized as a potent skeleton of MβLs inhibitors. All the compounds displayed inhibitory activity against ImiS with an IC(50) value range of 0.032–15.64 μM except 7. The chlorine substituted compounds (1, 2 and 3) inhibited NDM-1 with an IC(50) value of less than 0.96 μM, and the fluorine substituted 12 and 13 inhibited VIM-2 with IC(50) values of 38.9 and 2.8 μM, respectively. However, none of the triazolethioacetamides exhibited activity against L1 at inhibitor concentrations of up to 1 mM. Enzyme inhibition kinetics revealed that 9 and 13 are mixed inhibitors for ImiS with K(i) values of 0.074 and 0.27μM using imipenem as the substrate. Docking studies showed that 1 and 9, which have the highest inhibitory activity against ImiS, fit the binding site of CphA as a replacement of ImiS via stable interactions between the triazole group bridging ASP120 and hydroxyl group bridging ASN233. MDPI 2019-03-25 /pmc/articles/PMC6471427/ /pubmed/30934584 http://dx.doi.org/10.3390/molecules24061174 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Zhang, Yilin
Yan, Yong
Liang, Lufan
Feng, Jie
Wang, Xuejun
Li, Li
Yang, Kewu
Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title_full Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title_fullStr Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title_full_unstemmed Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title_short Halogen-Substituted Triazolethioacetamides as a Potent Skeleton for the Development of Metallo-β-Lactamase Inhibitors
title_sort halogen-substituted triazolethioacetamides as a potent skeleton for the development of metallo-β-lactamase inhibitors
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471427/
https://www.ncbi.nlm.nih.gov/pubmed/30934584
http://dx.doi.org/10.3390/molecules24061174
work_keys_str_mv AT zhangyilin halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT yanyong halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT lianglufan halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT fengjie halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT wangxuejun halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT lili halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors
AT yangkewu halogensubstitutedtriazolethioacetamidesasapotentskeletonforthedevelopmentofmetalloblactamaseinhibitors